Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

ALTON The statistics surrounding the incidence rate of lung cancer nationally, state-wide, and locally can literally take your breath away.According to ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC), a common type of lung cancer, to study the development, activity, and ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease ... a plasma cell cancer, could potentially be repurposed to treat IPF.